<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36914582</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial bioenergetic changes in systemic lupus erythematosus immune cell subsets: Contributions to pathogenesis and clinical applications.</ArticleTitle><Pagination><StartPage>603</StartPage><EndPage>611</EndPage><MedlinePgn>603-611</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231164635</ELocationID><Abstract><AbstractText>The association of dysregulated metabolism in systemic lupus erythematosus (SLE) pathogenesis has prompted investigations into metabolic rewiring and the involvement of mitochondrial metabolism as a driver of disease through NLRP3 inflammasome activation, disruption of mitochondrial DNA maintenance, and pro-inflammatory cytokine release. The use of Agilent Seahorse Technology to gain functional <i>in situ</i> metabolic insights of selected cell types from SLE patients has identified key parameters that are dysregulated during disease. Mitochondrial functional assessments specifically can detect dysfunction through oxygen consumption rate (OCR), spare respiratory capacity, and maximal respiration measurements, which, when coupled with disease activity scores could show potential as markers of disease activity. CD4+ and CD8 + T cells have been assessed in this way and show that oxygen consumption rate, spare respiratory capacity, and maximal respiration are blunted in CD8 + T cells, with results not being as clear cut in CD4 + T cells. Additionally, glutamine, processed by mitochondrial substrate level phosphorylation is emerging as a key role player in the expansion and differentiation of Th1, Th17, &#x3d2;&#x3b4; T cells, and plasmablasts. The role that circulating leukocytes play in acting as bioenergetic biomarkers of diseases such as diabetes suggests that this may also be a tool to detect preclinical SLE. Therefore, the metabolic characterization of immune cell subsets and the collection of metabolic data during interventions is also essential. The delineation of the metabolic tuning of immune cells in this way could lead to novel strategies in treating metabolically demanding processes characteristic of autoimmune diseases such as SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yennemadi</LastName><ForeName>Anjali S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0003-4875-9051</Identifier><AffiliationInfo><Affiliation>TB Immunology Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, St James's Hospital, Trinity College Dublin, The University of Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keane</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>TB Immunology Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, St James's Hospital, Trinity College Dublin, The University of Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leisching</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>TB Immunology Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, St James's Hospital, Trinity College Dublin, The University of Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">glutamate</Keyword><Keyword MajorTopicYN="N">glutamine</Keyword><Keyword MajorTopicYN="N">glycolysis</Keyword><Keyword MajorTopicYN="N">immunometabolism</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">oxygen consumption rate (OCR)</Keyword><Keyword MajorTopicYN="N">substrate level phosphorylation</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>13</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36914582</ArticleId><ArticleId IdType="pmc">PMC10155285</ArticleId><ArticleId IdType="doi">10.1177/09612033231164635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Takeshima Y, Iwasaki Y, Fujio K, et al.Metabolism as a key regulator in the pathogenesis of systemic lupus erythematosus. Semin Arthritis Rheum 2019; 48(6): 1142&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">31056210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H, Mohan C. Connective tissue diseases: promises and challenges of metabolomics in SLE. Nat Rev Rheumatol 2016; 12(11): 627&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">27708401</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Choi S-C, Xu Z, et al.Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med 2015; 7(274): 274ra18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5292723</ArticleId><ArticleId IdType="pubmed">25673763</ArticleId></ArticleIdList></Reference><Reference><Citation>Buang N, Tapeng L, Gray V, et al.Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. Nat Commun 2021; 12(1): 1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012390</ArticleId><ArticleId IdType="pubmed">33790300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Sanin DE, Everts B, et al.Type 1 interferons induce changes in core metabolism that are critical for immune function. Immunity 2016; 44(6): 1325&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5695232</ArticleId><ArticleId IdType="pubmed">27332732</ArticleId></ArticleIdList></Reference><Reference><Citation>Caielli S, Cardenas J, de Jesus AA, et al.Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. Cell 2021; 184(17): 4464&#x2013;4479.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380737</ArticleId><ArticleId IdType="pubmed">34384544</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Costa Reis P, et al.New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 2016; 12(12): 716&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Spier A, Connor MG, Steiner T, et al.Mitochondrial respiration restricts listeria monocytogenes infection by slowing down host cell receptor recycling. Cell Rep 2021; 37(6): 109989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595641</ArticleId><ArticleId IdType="pubmed">34758302</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill LAJ, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med 2016; 213(1): 15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710204</ArticleId><ArticleId IdType="pubmed">26694970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirose S, Lin Q, Ohtsuji M, et al.Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis. Int Immunol 2019; 31(11): 687&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794944</ArticleId><ArticleId IdType="pubmed">31063541</ArticleId></ArticleIdList></Reference><Reference><Citation>Stathopoulou C, Ntassis V, Banos A, et al.P107 Interferon-induced metabolic perturbations shape the inflammatory status of human monocytes: implications for innovative therapeutic engineering in SLE autoimmunity. In: 12th European lupus meeting 2020, Bruges, Belgium, 25&#x2013;27 March 2020.</Citation></Reference><Reference><Citation>McGarry T, Hanlon MM, Marzaioli V, et al.Rheumatoid arthritis CD14+ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease. Clin Transl Immunology 2021; 10(1): e1237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7815439</ArticleId><ArticleId IdType="pubmed">33510894</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambold AS, Pearce EL. Mitochondrial dynamics at the interface of immune cell metabolism and function. Trends Immunol 2018; 39(1): 6&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">28923365</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y, Takeshima Y, Fujio K. Basic mechanism of immune system activation by mitochondria. Immunol Med 2020; 43(4): 142&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">32393116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chacko BK, Kramer PA, Ravi S, et al.The bioenergetic health index: a new concept in mitochondrial translational research. Clin Sci 2014; 127(6): 367&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202728</ArticleId><ArticleId IdType="pubmed">24895057</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco LP, Pedersen HL, Wang X, et al.Improved mitochondrial metabolism and reduced inflammation following attenuation of murine lupus with coenzyme Q10 analog idebenone. Arthritis Rheumatol 2020; 72(3): 454&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050361</ArticleId><ArticleId IdType="pubmed">31566908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P-M, Katsuyama E, Satyam A, et al.CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci Adv 2022; 8(24): eabo4271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9200274</ArticleId><ArticleId IdType="pubmed">35704572</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K, Lauritzen KH, Olsen MB, et al.Low cellular NAD+ compromises lipopolysaccharide-induced inflammatory responses via inhibiting TLR4 signal transduction in human monocytes. J Immunol 2019; 203(6): 1598&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pubmed">31427442</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Singh K, Lin A, et al.Boosting NAD+ blunts TLR4-induced type I IFN in control and systemic lupus erythematosus monocytes. J Clin Invest 2022; 132(5): e139828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8884917</ArticleId><ArticleId IdType="pubmed">35025762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumikawa MH, Iwata S, Zhang M, et al.An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. Rheumatology 2022; 61(7): 3049&#x2013;3059.</Citation><ArticleIdList><ArticleId IdType="pubmed">34730825</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417(1): 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605959</ArticleId><ArticleId IdType="pubmed">19061483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vig S, Lambooij JM, Zaldumbide A, et al.Endoplasmic reticulum-mitochondria crosstalk and beta-cell destruction in type 1 diabetes. Front Immunol 2021; 12: 669492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8085402</ArticleId><ArticleId IdType="pubmed">33936111</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimessi A, Previati M, Nigro F, et al.Mitochondrial reactive oxygen species and inflammation: molecular mechanisms, diseases and promising therapies. Int J Biochem Cell Biol 2016; 81: 281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">27373679</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bruggen R, K&#xf6;ker MY, Jansen M, et al.Human NLRP3 inflammasome activation is Nox1-4 independent. Blood 2010; 115(26): 5398&#x2013;5400.</Citation><ArticleIdList><ArticleId IdType="pubmed">20407038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, McLean AS. The role of mitochondria in the immune response in critical illness. Crit Care 2022; 26(1): 80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957137</ArticleId><ArticleId IdType="pubmed">35337333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergely P, Niland B, Gonchoroff N, et al.Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol 2002; 169(2): 1092&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020441</ArticleId><ArticleId IdType="pubmed">12097418</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Hu X, Xiao F, et al.Mitochondrial impairment and repair in the pathogenesis of systemic lupus erythematosus. Front Immunol 2022; 13: 929520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358979</ArticleId><ArticleId IdType="pubmed">35958572</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong C, Song W, Fu T. Systemic inflammatory response syndrome is triggered by mitochondrial damage (review). Mol Med Rep 2022; 25(4): 147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8915392</ArticleId><ArticleId IdType="pubmed">35234261</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP, Hartley RC. Mitochondria as a therapeutic target for common pathologies. Nat Rev Drug Discov 2018; 17(12): 865&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">30393373</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang N, Perl A. Metabolism as a target for modulation in autoimmune diseases. Trends Immunol 2018; 39(7): 562&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">29739666</ArticleId></ArticleIdList></Reference><Reference><Citation>Voronov E, Dayan M, Zinger H, et al.IL-1&#x392;-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw 2006; 17(2): 109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">16840029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kegerreis BJ, Catalina MD, Geraci NS, et al.Genomic identification of low-density granulocytes and analysis of their role in the pathogenesis of systemic lupus erythematosus. J Immunol 2019; 202(11): 3309&#x2013;3317.</Citation><ArticleIdList><ArticleId IdType="pubmed">31019061</ArticleId></ArticleIdList></Reference><Reference><Citation>da Cruz HLA, Cavalcanti CAJ, de Az&#xea;vedo Silva J, et al.Differential expression of the inflammasome complex genes in systemic lupus erythematosus. Immunogenetics 2020; 72(4): 217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">32020248</ArticleId></ArticleIdList></Reference><Reference><Citation>Duraj T, Carri&#xf3;n-Navarro J, Seyfried TN, et al.Metabolic therapy and bioenergetic analysis: the missing piece of the puzzle. Mol Metab 2021; 54: 101389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637646</ArticleId><ArticleId IdType="pubmed">34749013</ArticleId></ArticleIdList></Reference><Reference><Citation>Titov AA, Baker HV, Brusko TM, et al.Metformin inhibits the type 1 IFN response in human CD4+ T cells. J Immunol 2019; 203(2): 338&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6615983</ArticleId><ArticleId IdType="pubmed">31160534</ArticleId></ArticleIdList></Reference><Reference><Citation>Saragovi A, Abramovich I, Omar I, et al.Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest. Elife 2020; 9: e56612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7728436</ArticleId><ArticleId IdType="pubmed">33226340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol 2020; 16(2): 100&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">31949287</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson MO, Wolf MM, Madden MZ, et al.Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell 2018; 175(7): 1780&#x2013;1795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6361668</ArticleId><ArticleId IdType="pubmed">30392958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono M, Yoshida N, Maeda K, et al.Glutaminase 1 inhibition reduces glycolysis and ameliorates lupus&#x2010;like disease in MRL/lpr mice and experimental autoimmune encephalomyelitis. Arthritis Rheumatol 2019; 71(11): 1869&#x2013;1878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817384</ArticleId><ArticleId IdType="pubmed">31233276</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Liu L, Yin Z, et al.Glutamine metabolism is essential for the production of IL-17A in &#x3b3;&#x3b4; T cells and skin inflammation. Tissue Cell 2021; 71: 101569.</Citation><ArticleIdList><ArticleId IdType="pubmed">34146944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogando DG, Choi M, Shyam R, et al.Ammonia sensitive SLC4A11 mitochondrial uncoupling reduces glutamine induced oxidative stress. Redox Biol 2019; 26: 101260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6604051</ArticleId><ArticleId IdType="pubmed">31254733</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P-M, Tsokos GC. Mitochondria in the pathogenesis of systemic lupus erythematosus. Curr Rheumatol Rep 2022; 24: 88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">35290598</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake R, Trounce IA. Mitochondrial dysfunction and complications associated with diabetes. Biochim Biophys Acta 2014; 1840(4): 1404&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pubmed">24246956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer PA, Chacko BK, George DJ, et al.Decreased bioenergetic health index in monocytes isolated from the pericardial fluid and blood of post-operative cardiac surgery patients. Biosci Rep 2015; 35(4): e00237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4613711</ArticleId><ArticleId IdType="pubmed">26181371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chacko BK, Smith MR, Johnson MS, et al.Mitochondria in precision medicine; linking bioenergetics and metabolomics in platelets. Redox Biol 2019; 22: 101165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436140</ArticleId><ArticleId IdType="pubmed">30877854</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Arnaud L. The main challenges in systemic lupus erythematosus: where do we stand? J Clin Med 2021; 10(2): 243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7827672</ArticleId><ArticleId IdType="pubmed">33440874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambers WM, Westra J, Bootsma H, et al.From incomplete to complete systemic lupus erythematosus; a review of the predictive serological immune markers. Semin Arthritis Rheum 2021; 51(1): 43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">33360229</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra J, Bootsma H, de Leeuw K. From incomplete to complete systemic lupus erythematosus; a review of the predictive serological immune markers. Semin Arthritis Rheum 2020; 51(1): 43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">33360229</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio J, Kyttaris VC. Measuring IFN activity in suspected SLE: a valuable step? Expert Rev Clin Immunol 2021; 17(6): 545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">33827358</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>